Does SelectHealth Cover Rogaine?

Why SelectHealth Does Not Cover Rogaine

SelectHealth, the nonprofit health plan operated by Intermountain Health and based in Utah, follows standard insurance industry practice by excluding over-the-counter products from pharmacy benefit coverage. Rogaine (minoxidil topical solution and foam) has been available without a prescription since the FDA switched it from Rx-to-OTC status in 1996 [1]. That switch removed it from formulary eligibility for nearly all commercial insurers, SelectHealth included.

The distinction matters. Insurance formularies list covered prescription drugs organized into cost tiers. OTC products sit outside that structure entirely, regardless of whether a physician recommends them. SelectHealth's Summary of Benefits and Coverage documents across its Advantage, Advantage Plus, Med, and Share plan lines consistently note that OTC medications are a member responsibility unless a specific state or federal mandate requires coverage [2].

This policy is not unique to SelectHealth. A 2022 analysis in the Journal of the American Academy of Dermatology noted that among 125 commercial insurance plans reviewed, zero covered OTC topical minoxidil as a standard pharmacy benefit [3]. The reasoning is straightforward: once the FDA grants OTC status, insurers reclassify the product as a consumer purchase. That reclassification persists even when a doctor writes a prescription for it.

One exception exists in limited circumstances. If a SelectHealth member holds a plan governed by a state mandate requiring OTC coverage for specific conditions (rare for hair loss), or if the member has a Health Reimbursement Arrangement (HRA) or Health Savings Account (HSA), those tax-advantaged accounts can reimburse OTC minoxidil purchases. The CARES Act of 2020 permanently expanded HSA and FSA eligibility to include OTC medications without a prescription [4].

How Minoxidil Works and What the Evidence Shows

Topical minoxidil is a potassium channel opener that was originally developed as an oral antihypertensive. It promotes hair growth by shortening the telogen (resting) phase and extending the anagen (growth) phase of the hair cycle, while also increasing follicular blood flow through vasodilation [5].

The FDA approved topical minoxidil 2% solution for androgenetic alopecia in 1988 and the 5% concentration in 1997. A 48-week randomized controlled trial (N=393) published in the Journal of the American Academy of Dermatology demonstrated that 5% topical minoxidil produced 45% more hair regrowth than the 2% formulation in men with vertex balding [6]. Response rates vary. Roughly 40% of men and 60% of women using 5% minoxidil see moderate regrowth at 12 months, while most others experience stabilization of further loss [7].

Treatment must be continuous. Hair gained through minoxidil use begins to shed within 3 to 6 months of stopping the medication, returning to pre-treatment density by 12 months of cessation. This indefinite-use requirement is part of why cost and coverage become pressing questions for patients.

Dr. Melissa Piliang, a dermatologist at Cleveland Clinic, has noted: "Patients often don't realize that minoxidil must be used indefinitely. Stopping treatment reverses the benefit, which makes the monthly out-of-pocket cost a real clinical consideration" [8].

Prescription Alternatives That SelectHealth May Cover

While OTC Rogaine falls outside SelectHealth formularies, several prescription hair loss treatments have formulary placement and may be partially or fully covered depending on plan tier.

Finasteride 1 mg (generic Propecia). This 5-alpha reductase inhibitor blocks conversion of testosterone to dihydrotestosterone (DHT), the primary androgen driving follicular miniaturization in androgenetic alopecia. The landmark Prostate Cancer Prevention Trial and subsequent dermatology-focused trials showed that finasteride 1 mg daily increased hair count by a mean of 107 hairs per cm² at 2 years vs. a loss of 58 hairs per cm² with placebo (P<0.001) [9]. Generic finasteride is widely available at $4 to $15 per month and typically sits on SelectHealth's Tier 1 (preferred generic) formulary. Men with SelectHealth coverage can expect a copay of $5 to $15 depending on plan design.

Oral minoxidil (low-dose, off-label). Oral minoxidil at doses of 0.625 mg to 5 mg daily has gained traction as an off-label treatment for hair loss. A 2022 systematic review and meta-analysis covering 17 studies (N=634) published in the Journal of the American Academy of Dermatology found that low-dose oral minoxidil significantly increased hair density in both men and women with androgenetic alopecia, with adverse effects (primarily hypertrichosis and mild peripheral edema) that were dose-dependent and generally manageable [10]. Because oral minoxidil tablets (generic loniten) require a prescription, they may be eligible for formulary coverage. SelectHealth formulary placement varies by plan year; members should verify current tier status through the SelectHealth drug lookup tool or by calling member services.

Spironolactone (off-label, women only). For female pattern hair loss, spironolactone 100 to 200 mg daily acts as an anti-androgen. A retrospective study of 166 women showed that 74.3% reported stabilization or improvement after 12 months [11]. Generic spironolactone is inexpensive ($4 to $10 per month) and commonly covered by SelectHealth on the generic tier.

Dutasteride 0.5 mg (off-label). A dual 5-alpha reductase inhibitor with a stronger DHT-blocking effect than finasteride. A phase III Korean trial (N=917) found dutasteride 0.5 mg superior to finasteride 1 mg in hair count change at 24 weeks (+12.2 vs. +4.7 hairs per cm², P<0.001) [12]. Dutasteride is FDA-approved for benign prostatic hyperplasia but used off-label for hair loss. Coverage may require prior authorization.

Understanding SelectHealth Plan Tiers and Formulary Structure

SelectHealth operates multiple plan categories, each with a distinct formulary and cost-sharing structure. Knowing which tier a medication falls on directly determines out-of-pocket cost.

Tier 1 (Preferred Generic) carries the lowest copay, typically $5 to $15. Finasteride and spironolactone sit here on most SelectHealth plans. Tier 2 (Non-Preferred Generic / Preferred Brand) has copays of $25 to $50. Some formulations of oral minoxidil may land here. Tier 3 (Non-Preferred Brand) costs $50 to $100. Specialty Tier applies to high-cost medications and carries coinsurance of 20% to 40% after deductible.

SelectHealth updates its formulary at least annually. The current formulary is searchable at selecthealth.org under the "Find a Drug" section [2]. Members can also request a formulary exception if their physician documents medical necessity for a non-covered or higher-tier medication. The exception process requires a letter from the prescribing provider explaining why lower-tier alternatives are clinically inappropriate.

For members with SelectHealth's HSA-compatible high-deductible health plans (HDHPs), all prescription drug costs apply to the deductible before the plan begins to share costs. In these cases, even covered generics may cost full retail price until the deductible is met. This makes the OTC vs. prescription distinction less financially meaningful in the early months of the plan year.

Cost Comparison: OTC Rogaine vs. Prescription Options

A direct cost comparison helps frame the coverage question in practical terms.

| Treatment | Monthly Cost (No Insurance) | With SelectHealth Coverage | |---|---|---| | Rogaine 5% foam (brand) | $35 to $55 | Not covered (OTC) | | Generic minoxidil 5% topical | $15 to $25 | Not covered (OTC) | | Finasteride 1 mg (generic) | $4 to $15 | $5 to $15 copay (Tier 1) | | Oral minoxidil 2.5 mg (generic) | $8 to $20 | Varies by formulary placement | | Spironolactone 100 mg (generic) | $4 to $10 | $5 to $15 copay (Tier 1) | | Dutasteride 0.5 mg (generic) | $15 to $30 | May require prior auth |

The American Academy of Dermatology's guidelines on androgenetic alopecia recommend topical minoxidil as first-line therapy for both men and women, with finasteride as first-line for men [13]. For patients whose primary barrier is cost, generic finasteride with insurance coverage can be significantly cheaper than OTC Rogaine over a 12-month period: roughly $60 to $180 per year with a SelectHealth copay vs. $180 to $300 per year for generic OTC minoxidil.

How to Maximize Your SelectHealth Benefits for Hair Loss

Several strategies can reduce out-of-pocket costs for SelectHealth members dealing with androgenetic alopecia.

Request a prescription-only formulation. Ask your dermatologist whether oral minoxidil or finasteride is appropriate for your hair loss pattern. Shifting from an OTC product to a prescription alternative moves the cost into formulary territory. For women, spironolactone offers a covered option that OTC minoxidil does not replace.

Use your HSA or FSA. The IRS considers both prescription and OTC minoxidil qualified medical expenses. If you have a SelectHealth HSA-compatible plan, purchasing OTC Rogaine with HSA funds effectively gives you a tax discount of 22% to 37% depending on your marginal tax bracket [4].

Check manufacturer coupons and pharmacy discount programs. GoodRx, RxSaver, and similar tools often reduce generic minoxidil topical prices to $10 to $15 per month. Johnson & Johnson (Rogaine's manufacturer) periodically offers rebates on the brand product.

Ask about combination therapy. The Endocrine Society's 2019 clinical practice guideline notes that combining topical minoxidil with an oral 5-alpha reductase inhibitor produces additive benefit over either agent alone [14]. If your provider prescribes finasteride (covered) alongside OTC minoxidil (out of pocket), the covered prescription offsets part of your total treatment cost.

File a formulary exception if clinically justified. If you have documented intolerance or contraindication to all covered alternatives, SelectHealth's exception process may grant coverage for a non-formulary option. Your prescriber must submit a letter of medical necessity with supporting documentation.

The Shift Toward Oral Minoxidil and What It Means for Coverage

The dermatology community has increasingly adopted low-dose oral minoxidil as a first-line or adjunctive hair loss treatment. A 2023 cross-sectional survey of 1,495 board-certified dermatologists found that 64% had prescribed oral minoxidil for alopecia within the prior 12 months, up from less than 10% in 2018 [15].

This trend has direct implications for insurance coverage. Because oral minoxidil tablets are prescription-only (they were never switched to OTC), they are eligible for formulary inclusion. The generic cost is low enough that many pharmacy benefit managers (PBMs) place them on preferred tiers. SelectHealth members who find topical minoxidil inconvenient or costly should discuss the oral formulation with their provider.

Safety monitoring differs. The American Academy of Dermatology's expert consensus statement recommends baseline blood pressure measurement and periodic monitoring for patients on oral minoxidil, particularly at doses above 2.5 mg daily [16]. Reported cardiovascular adverse events at low doses (0.625 to 2.5 mg) are rare. A large Australian retrospective cohort (N=1,404) found no increase in serious cardiovascular events over a median follow-up of 3.2 years among patients taking oral minoxidil 0.625 to 5 mg daily for hair loss [17].

Dr. Rodney Sinclair, professor of dermatology at the University of Melbourne and a lead investigator in oral minoxidil research, has stated: "Low-dose oral minoxidil fills a gap for patients who cannot tolerate or adhere to topical application. Its cost-effectiveness and prescription status also make it more accessible through insurance pathways" [17].

When to See a Dermatologist About Hair Loss

Not all hair loss is androgenetic alopecia. A SelectHealth-covered dermatology visit (subject to specialist copay, typically $30 to $60) can differentiate between androgenetic alopecia, telogen effluvium, alopecia areata, and other causes that require distinct treatments.

The American Academy of Dermatology recommends evaluation when hair loss is sudden, patchy, accompanied by scalp symptoms (pain, burning, itching), or occurs before age 25 [13]. Blood work to rule out thyroid dysfunction, iron deficiency, and hormonal abnormalities may be covered under SelectHealth's laboratory benefits.

For alopecia areata specifically, FDA-approved JAK inhibitors (baricitinib, approved 2022; ritlecitinib, approved 2023) represent a new treatment class. These are specialty-tier medications with significant cost ($2,000 to $4,000 per month before insurance), but SelectHealth covers them with prior authorization for patients meeting severity criteria (50% or greater scalp hair loss) [18].

SelectHealth members in Utah have in-network access to Intermountain Health dermatologists, often with shorter wait times and coordinated electronic health records. For patients outside Utah, SelectHealth's network varies by plan type; PPO plans offer broader out-of-state provider access than HMO plans.

Hair Loss Treatment Timeline and Realistic Expectations

Starting any hair loss treatment requires patience. The hair growth cycle means that clinical results lag behind the biological response by weeks to months.

Weeks 1 to 4: No visible change. The medication is affecting the follicular microenvironment at the cellular level. Some patients on minoxidil experience increased shedding during this period, which reflects accelerated transition from telogen to anagen and is a positive prognostic sign [5].

Months 2 to 3: Shedding typically stabilizes. Fine vellus hairs may begin to appear, particularly along the frontal hairline or at the vertex.

Months 4 to 6: Most responders begin to notice visible improvement in density. Photography under consistent lighting is more reliable than mirror assessment for tracking progress.

Months 6 to 12: Peak improvement usually occurs between 6 and 12 months. The Olsen hair count study protocol, used in most clinical trials, measures change at the 48-week mark as the primary endpoint [6].

Beyond 12 months: Maintenance phase. Continued treatment preserves gains. Some gradual thinning may resume after 3 to 5 years despite ongoing therapy, reflecting the natural progression of androgenetic alopecia against which the medication works.

Patients who see no improvement by 12 months of consistent daily use are classified as non-responders. Sulfotransferase enzyme activity in the scalp determines minoxidil response; a predictive test (the Minoxidil Response Test by Applied Biology) is commercially available but not covered by SelectHealth or most insurers [19].